NCT06971900View on ClinicalTrials.gov

GATEWAY: A Phase 2a Study of PORT-77 in Adults With Erythropoietic Protoporphyria

PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

April 4, 2025

Primary Completion Date

January 1, 2026

Study Completion Date

January 31, 2026

Conditions
Erythropoietic Protoporphyria (EPP)
Interventions
DRUG

PORT-77

Active oral dose form

DRUG

Placebo

Matching inactive oral dose form

Trial Locations (1)

85283

Celerion, Tempe

Sponsors

Collaborators (1)

Celerion
All Listed Sponsors
collaborator

Celerion

INDUSTRY

lead

Portal Therapeutics, Inc.

INDUSTRY

NCT06971900 - GATEWAY: A Phase 2a Study of PORT-77 in Adults With Erythropoietic Protoporphyria | Biotech Hunter | Biotech Hunter